Monthly Archives: April 2022

Pacritinib Added to NCCN Recommendation for Treatment in MPNs – Targeted Oncology

Posted: April 19, 2022 at 2:23 am

The National Comprehensive Cancer Network has announced their recommendation for the use of pacritinib in the first line and second line setting for treating patients with myeloproliferative neoplasms.

The novel kinase inhibitor pacritinib (Vonjo) was added to the latest National Comprehensive Cancer Network (NCCN) guidelines as a recommended treatment for patients with myeloproliferative neoplasms (MPN), according to a press release.1

"We are grateful that the NCCN acted quickly to include (pacritinib) with a Category 2A designation in its Clinical Practice Guidelines in Oncology as a first line treatment for high-risk patients with myelofibrosis with platelet counts less than 50 x 109/L who are not candidates for transplant, said Adam R. Craig, MD, PhD, president, and chief executive officer of CTI BioPharma, in a statement. This therapeutic option helps address an unmet medical need for patients who previously have no other treatment options. There is no other FDA-approved first line treatment for these patients with a 2A designation within the NCCN guidelines.

Pacritinib was approved by the FDA earlier this year for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L. In addition to this designation from the FDA, the NCCN has recommended pacritinib as a second-line treatment in low-risk and high-risk patients with myelofibrosis who have a platelet count greater than 50 x 109/L who are also not candidates for transplant. According to Craig, this will allow for even more treatment options in patients with MPNs.

The JAK family of enzymes promotes normal blood cell growth in patients because JAK is central component in signal transaction pathways, meaning that there is a direct relationship between mutations in these pathways and the development of hematological cancers like MPNs. Thus, allowing pacritinib to impact the development of the disease.

In the US, there are approximately 21,000 patients with myelofibrosis, two-thirds of which have cytopenias (thrombocytopenia or anemia), commonly resulting from the toxicity of other approved therapies, Craig said in a press release when announcing the FDA approval of pacritinib.2 Severe thrombocytopenia, defined as a blood platelet count below 50 109/L, occurs in one-third of the overall myelofibrosis population, and has a particularly poor prognosis.

Results from the phase 3 PERSIST-1 (NCT01773187), phase 3 PERSIST-2 (NCT02055781), and phase2 dose-finding PAC203 trial led to the initial approval, and now recommendation by the NCCN, for the use of pacritinib in multiple lines of therapy for patients with MPNs. These findings demonstrated that the kinase inhibitor, with specificity for inhibiting JAK2 and IRAK1 without inhibiting JAK1, was associated with better outcomes in patients in comparison to the best available therapy.

After the PERSIST-1 trial met its primary endpoint at week 24 of the study when 19% of patients on pacritinib had a spleen reduction size by 35% or more compared to 5% in the control group, 311 patients enrolled in the PERSIST-2 trial saw better results on pacritinib given twice a day.3 Eighteen percent of patients in the twice daily pacritinib arm of the trial had a spleen reduction of 35% or greater vs 3% in the best available therapy arm.4

The most common adverse events (AEs) observed on twice-daily pacritinib at 200 mg, seen in 20% or more of paitents, was diarrhea, thrombocytopenia, nausea, anemia and peripheral edema. Serious AEs seen in 3% or more of patients on the same regimen were anemia, thrombocytopenia, pneumonia, cardiac failure, disease progression, pyrexia, and squamous cell carcinoma of skin.

The approval of pacritinib establishes a new standard of care for myelofibrosis patients suffering from cytopenic myelofibrosis," said John Mascarenhas, MD, associate professor, Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, in a press release on the approval of the drug. "Myelofibrosis with severe thrombocytopenia, defined as blood platelet counts below 50 109/L, has been shown to result in poor survival outcomes coupled with debilitating symptoms. Limited treatment options have rendered this disease an area of urgent unmet medical need."

References

1. NCCN Guidelines Recommend VONJO (pacritinib) for the Treatment of Myeloproliferative Neoplasms. CTI BioPharma Corp. News release. April 14, 2022. Accessed April 14, 2022. https://prn.to/3EiDaN0

2. CTI BioPharma announces FDA accelerated approval of VONJO (pacritinib) for the treatment of adult patients with myelofibrosis and thrombocytopenia. CTI BioPharma Corp. News release. February 28, 2022. Accessed April 14, 2022. https://bit.ly/3vsDPsO

3. Mesa R, Vannuchhi A, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. The Lan. Hem. Published: March 20, 2017. doi: https://doi.org/10.1016/S2352-3026(17)30027-3

4. Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018;4(5):652659. doi:10.1001/jamaoncol.2017.5818

See the rest here:
Pacritinib Added to NCCN Recommendation for Treatment in MPNs - Targeted Oncology

Posted in Cell Medicine | Comments Off

Behavioral health experts discuss the need for medical and behavioral reintegration and how to fill access gaps in Utah – State of Reform

Posted: April 19, 2022 at 2:22 am

Behavioral health experts in Utah highlighted the need to carve in behavioral health care accountable care organizations (ACOs) and fill gaps in the access to behavioral health care for rural and mild-to-moderate risk patients.

At our 2022 Utah State of Reform Health Policy Conference panel, An honest conversation about behavioral health, three behavioral health experts discussed the biggest needs for Utahns in the behavioral health space and how Utah is attempting to address these needs.

Get the latest state-specific policy intelligence for the health care sector delivered to your inbox.

The panelists were Mark Rapaport, Chief Executive Officer of the Huntsman Mental Health Institute, Scott Whittle, M.D., Medical Director at SelectHealth, and Patrick Fleming, Former Director of the Salt Lake County Division of Behavioral Health Services.

Rapaport outlined the behavioral health struggles in Utah and around the country in numbers, saying suicide is the number one killer of all Uthans between the ages of 10 and 24 and the number two killer nationwide for the same age group.

He noted that 75% of all mental disorders appear between the ages of 10 and 24. The early onset of these disorders makes preventative care and access to care for the mild-to-moderate risk demographic so important, said Rapaport.

He is also concerned about the effect stigma has on expanding and receiving quality access to behavioral health care. The University of Utah (UofU) is kicking off a 10-year initiative to attempt to eradicate stigma around behavioral health and substance use disorders.

If we dont do that, we are never going to handle the issues of parity, said Rapaport.

Though these issues have been prevalent in Utah for some time, seven years ago, Utah was more concerned about the continual increase in the cost of health care and coverage. To help curb these costs, the legislature created accountable care organizations (ACOs), in which a group of providers are held accountable for the quality of care they provide by having their payments tied to quality metrics. This payment structure aims to lower costs and improve health outcomes.

However, Medicaid behavioral health is not managed by ACOs and is a carve out run on a capitation model by the counties in Utah. The panelists said Medicaid medical and behavioral health need to be integrated and that behavioral health needs to be carved in due to the intertwined nature of medical and behavioral health.

Whittle said that the capitation model currently used by Medicaid when providing behavioral health is nearly impossible to navigate due to the amount of intertwined comorbidities many behavioral health patients have when seeking care. Whittle said Utah needs to merge these two payment models and reintegrate medical and behavioral health.

It is not my responsibility in being in charge of the medical risk, but it is my problem, said Whittle.

Fleming expressed some of the challenges that he thinks will be faced before this reintegration. We will make a change and we will come out really well on this. Is it going to be easy? No, there are some people who are going to want to resist this, said Fleming.

Next, the panelists discussed the many gaps to access to behavioral health care found throughout the state. With the ACO model, counties typically pay and care for those who are in most need. This ends up leaving out many Utahns with mild-to-moderate behavioral health concerns, which causes more Utahns to slip through the cracks of the system.

Rapaport described the need for spaces to deal with crisis management that are not emergency departments (EDs), where most people in crisis end up going to now. He said folks in behavioral health crises suffer the longest wait times and release times in EDs.

That is why UofU is creating a new crisis care center in a place near the university where people who need the most help are. This center will take anyone, regardless of their ability to pay, and has in-patient beds and staff to assist those in crisis. The center will be partnering with law enforcement to reduce the number of those in crisis ending up in jail.

We need to create a place of dignity where we can deliver appropriate care for individuals, said Rapaport.

He said the UofU will continue to create legal clinics for those having trouble with the law, dental clinics, and family medicine clinics to best meet those in need where they are at.

Posted in Preventative Medicine | Comments Off

Your Healthy Family: Rise in cancer is unintended consequence of pandemic – FOX 4 News Fort Myers WFTX

Posted: April 19, 2022 at 2:22 am

NAPLES, Fla. A doctor at NCH Healthcare System said one unintended consequence of the COVID-19 pandemic is a rise in cancer patients, especially patients with late stage cancer.

During the height of the pandemic, Dr. David Lindner the Subdivision Head of Pulmonary and Critical Care Medicine at NCH Healthcare System said COVID-19 took over everything.

"It was COVID, COVID, COVID, and COVID. Basically all consuming, he said.

Dr. Lindner said that meant other things, like preventative care, weren't happening as usual.

"Screening, mammograms, colonoscopies, labs, X-rays, doctors visits, everything just got thrown to the wayside," he said. "One of the big unintended consequences is now we are seeing that some of these problems have come home to roost.

Dr. Lindner said NCH Healthcare System is seeing a rise in lung cancer patients, especially patients with late stage cancer.

Compared to the past, what we're seeing is that these cancers are more advanced. So instead of us diagnosing stage one and two, where surgical cure and other options of therapy are available, we've unfortunately seen an upswing in advanced stage three and four cancers," Dr. Lindner said.

In stage three and four, there are fewer treatment options and ways to cure the cancer. Dr. Lindner also said another unintended consequence of this pandemic, is that tobacco made an upswing.

"Why? Well, many people who were smokers, you have the stress of the pandemic, they unfortunately lit up again or continued to smoke," he said.

Smoking increases a person's risk of lung disease and lung cancer. Dr. Linder said if you haven't already, now is the time to get screened and not just for lung cancer.

"Women who have not gotten their mammograms, men who have not been checked out for prostate cancer it's time," Dr. Lindner said.

He said people who have a history of tobacco use and are older than 50 should get screened for lung cancer.

View post:
Your Healthy Family: Rise in cancer is unintended consequence of pandemic - FOX 4 News Fort Myers WFTX

Posted in Preventative Medicine | Comments Off

8 Early Signs You Have Lung Cancer, According to Doctors Eat This Not That – Eat This, Not That

Posted: April 19, 2022 at 2:22 am

Lung cancer is one of the most common cancers in the U.S., and it's the most common type of cancer death. According to the American Cancer Society, more people die of lung cancer each year than of colon, breast, and prostate cancer combined. Early detection is crucial. So is lung-cancer screening, for some groups of people. Read on to find out more about the early signs you have lung cancer, and if you should get screenedand to ensure your health and the health of others, don't miss these Sure Signs You've Already Had COVID.

"Unfortunately, most signs of lung cancer are not noticeable until the cancer has spread, but there are a few symptoms that can be a tell-tale sign for a doctor's visit," says Dr. Sonal Sura, a radiation oncologist with GenesisCare in Florida. "These symptoms include persistent coughing, coughing up blood rust-colored sputum (spit or phlegm) or hoarseness. Many people may view these symptoms as related to another ailment."

"Chest pain is a common symptom of many different medical conditions, including lung cancer," says Dr. Gethin Williams, an interventional oncologist in El Paso, Texas. "Lung cancer causes chest pain by irritating or compressing the nerves around your lungs. Other causes of chest pain include heart attack, angina, and pulmonary embolism. If you're experiencing chest pain that doesn't go away, see your doctor as soon as possible."

"If you have difficulty breathing or wheezing, it could be a sign of lung cancer," says Williams. "Lung cancer can obstruct the airways, making it difficult to breathe."

"One of the most common early symptoms of lung cancer most people might not know about is pneumonia that just doesn't seem to resolve," says Dr. Puja Uppal, a Michigan-based family medicine physician. "This, without a doubt, increases my suspicion for lung cancer."

RELATED: Habits Secretly Increasing Your Abdominal Fat, Say Physicians

"A sign of lung cancer most people don't know about is called an inspiratory stridor," says Uppal. "Our airway and lungs together are essentially a musical instrument. If there's a mass in your airway or lungs, it could obstruct the air you're breathing in and out. This obstruction causes a change in the flow of air that you're breathing in. The end result is an audible sound."6254a4d1642c605c54bf1cab17d50f1e

RELATED: Doing This After Age 60 is "Unhealthy," Say Physicians

"A fever can be caused by many different things, including lung cancer," says Williams. "Lung cancer can cause a fever by causing inflammation and the release of pro-inflammatory cytokines, small molecules that regulate the immune system. Also, lung cancer can block airways causing infection."

RELATED: I'm a Virus Expert and if You Have This Symptom, Get Help

"Lung cancer can cause excessive sweating by causing the body to overheat," says Williams. "This is because the cancerous cells use more energy and produce more heat than normal cells and cause the release of pro-inflammatory cytokines. Sweating is your body's way of trying to cool down."

"Weight loss is a common symptom of many different medical conditions, including lung cancer," says Williams. "Lung cancer causes weight loss because cancer diverts nutrients to itself, starving the body."

"When it comes to lung cancer, one of the most important things to know is that early detection can actually save your life," says Uppal. "I encourage all my patients to leverage preventative care services to achieve their best health outcomes. In this case, it would be getting a low-dose lung cancer screening CT scan (LDCT)."

The U.S. Preventive Services Task Force (USPSTF) recommends yearly lung cancer screening with LDCT for people who

A "pack-year" is defined as smoking an average of one pack of cigarettes per day for one year.

And to protect your life and the lives of others, don't visit any of these 35 Places You're Most Likely to Catch COVID.

Go here to see the original:
8 Early Signs You Have Lung Cancer, According to Doctors Eat This Not That - Eat This, Not That

Posted in Preventative Medicine | Comments Off

Allergies May Come With Heightened Risk of Heart Problems | The Weather Channel – Articles from The Weather Channel | weather.com – The Weather…

Posted: April 19, 2022 at 2:22 am

Allergy symptoms can certainly be frustrating at times. Whether you deal with itchy, watery eyes, sneezing, a runny nose, coughing, scratchy throat or all of the above, getting through allergy season can be a real slog. But there might be more to worry about with allergies than their short-term, nagging symptoms. A study of data from the National Health Interview Survey found allergies are also associated with an increased risk of developing heart problems later in life.

There have been previous studies that linked having allergies with cardiovascular disease before, but Yang Guo, PhD, the studys lead author, told Science Magazine there is a lot of disagreement over those findings in the scientific community. The aim of Guo's study was to parse National Health Interview Survey's data and ascertain whether there was indeed elevated cardiovascular risks associated with allergies.

The study looked at 34,417 adults surveyed in 2012. The allergic group was represented by 10,045 people who had at least one allergy ranging from seasonal to food to pet to medicine. The researchers made sure to adjust their findings to account for discrepancies caused by things like age, race, pre-existing conditions, BMI and whether the subjects were smokers or drinkers.

The analysis ultimately showed that adults between the ages of 18 and 57 with a history of allergies had an increased risk of developing high blood pressure, which can lead to heart conditions down the road. Black male adults between the ages of 39 to 57 had a higher risk of developing coronary heart disease. And people in the allergenic group who also had asthma were at the highest risk of developing both coronary heart disease and high blood pressure.

These findings will be presented American College of Cardiology Asia 2022 in April. The study's authors hope their work will lead to improvements in long-term preventative care for allergy sufferers. If there is potential for people with allergies to develop heart complications over time, it's important that their medical practitioner alert them to that risk early on, and provide them with options to help mitigate it.

Read the original post:
Allergies May Come With Heightened Risk of Heart Problems | The Weather Channel - Articles from The Weather Channel | weather.com - The Weather...

Posted in Preventative Medicine | Comments Off

Harper Care preps up with $6.5 million dosage to boost AI-based mental healthcare – Tech.eu

Posted: April 19, 2022 at 2:22 am

With over one billion people worldwide struggling with their mental health, London-based Harper Care has raised $6.5 million to address the issue. The round was led by Brydge Capital

Traditional mental health solutions such as conventional therapy typically require a diagnosis of illness. They are also expensive and hard to access, generally limiting their use to react to a crisis. Founded by Ved Sharma and Mithi Thaya, the startup aims to change the scenario with its delivery of hyper-personalised mental health support.

The health tech aims to make mental healthcare more objective, affordable and preventative through molecular biology and technology for earlier accurate detection. Its computational algorithm delivers to each patient personalised evidence-based interventions that incrementally alter behaviour and improve outcomes.

Dr Ved Sharma, founder and chief medical officer, Harper, said: We aim to reach a much wider group with our precision medicine approach to preventative mental healthcare. Due to the widespread negative impacts of elevated stress on patients living with physical illnesses, such as gastrointestinal and cardiometabolic disorders, or people facing the challenges of infertility, there is an urgent need for widely-available tools for preventative approaches to mental health.

Nick Hocart, partner, Brydge Capital, added: We have tracked the trend of an increase in investment in solutions targeting mental health. Most of them focus on supporting people usually when they are at their lowest point in health. We believe that Harper has the best-placed team to address the gap in the market where the emphasis is on prevention.

See original here:
Harper Care preps up with $6.5 million dosage to boost AI-based mental healthcare - Tech.eu

Posted in Preventative Medicine | Comments Off

2021 AAAS Fellows Share Their Experience in Scientific Research – The Chicago Maroon

Posted: April 19, 2022 at 2:21 am

The American Association for the Advancement of Science (AAAS) is the worlds largest multidisciplinary society for the sciences and a leading publisher of research. Each year, the AAAS Council elects Fellows for their research and its applications significant to science and society. In 2021, nine UChicago professors were named AAAS Fellows.

Phoebe A. Rice

Biochemistry and molecular biophysics professor Phoebe A. Rices research focuses on the fundamentals of biochemical systems, specifically how proteins control DNA and mobile genetic elements.

I think weve made a lot of contributions to understanding DNA rearrangement reactions from a very fundamental biochemistry point of viewhow they are orchestrated and controlled, Rice said. For the DNA rearrangement enzymes Im working on now, one of my hopes is that people can use the tools were developing to get microbes to make biofuels, which will be very useful to the planet.

Rice prizes the laboratory work involved in her research. I find [the laboratory work] amazingit shows the intricacies of how Mother Nature pulls things off, Rice said. To some degree, I view it almost as art. Its showing people how beautiful nature is even at the tiny level.

In the study of protein structures, there has been a recent revolution in artificial intelligence methods. Within the last year, artificial intelligence methods have gotten very good at looking at enormous databases of protein structures and sequences and then taking a new sequence and guessing the structure, Rice said. We can make predictions that give you testable hypotheseswithout even having to lift a pipette.

Amanda Woodward

Amanda Woodward, Dean of the Division of the Social Sciences and the William S. Gray Distinguished Service Professor of Psychology, is a founding member of UChicagos Center for Early Childhood Research. As a developmental psychologist, Woodward studies how infants make sense of other people's actions and interactions. Human beings are really intensely social species, Woodward said. So understanding who we are as thinkers, reasoners, and learners sort of depends on understanding how we react to the social context.

Woodwards most highly cited paper was published in 1998; it details her discovery that infants are able to recognize the difference between object and human movements and see the latter as goal-directed. It established a whole program of research in my lab and also inspired a lot of research around the world, Woodward said.

This was followed by another discovery that babies reasoning about other peoples behavior is directly connected with their motor development. Woodwards lab found that the babys own ability to use tools predicted how they were going to reason about other peoples actions and abilities.

During my lifetime, there have been really important discoveries in this field that have shaped what we know about the human mind and its development, so that makes it exciting to be in science and part of that discovery process. Thats what motivates my work, Woodward said.

Yoav Gilad

Professor of Medicine Yoav Gilad focuses on functional genomics, analyzing phenotypes at the molecular level to better understand clinically relevant differences between people.

One of the current projects that his lab is working on involves developing a new cell culture model using an in vitro system, which will allow them to characterize environmental interactions with human genomes during early development. If we're correct about the potential of this new system, then I believe that it can truly change the amount of insight we can have into patients' risk and response to medication, Gilad said. It can even help with developing new medicine by testing it much more rapidly in the lab before going through testing phases.

Gilads interest in this area was largely inspired by his study of olfaction while in pursuit of his doctorate degree. Through my work on olfaction, I became very interested not just in the different ways that we can smell things, but just in general the relationship between genes, environment, and our phenotypic differences, Gilad said. Over the last decade or so, I became interested in how we can use these tools to actually make an impact in the health system and in the clinic.

One of the most significant discoveries made by Gilad and his lab has been in the area of gene regulation and variation, where they produced one of the first maps to track rotary mechanisms. Another significant discovery comes from Gilads work in comparative genomics; Gilad and his team established the first panel of chimpanzee stem cells, which they now freely share with other scientists. I'm very proud that there are dozens of papers that are not from our lab, but use our cells, the resources that we developed, to really enhance that field, Gilad said.

Michael Coates

Michael Coates is a Professor of Organismal Biology and Anatomy whose research focuses on early vertebrate diversity and evolution. He is most interested in discovering morphology, the origin and form that underlies vertebrate body parts, using fossils to look at the early radiation of modern vertebrate groups. Coates works primarily with fish, and collaborates closely with fish labs that look at the developmental biology side of fish.

One of Coatess biggest accomplishments was discovering the earliest limbs with digits in his postdoctoral work. Coates and his colleagues found that the number of digits varied, as opposed to the widely accepted standard number of five digits. Although Coates has made several discoveries and contributions to the field of morphology, he continues to be fascinated by fundamental questions regarding the genetic path to morphology and what this means in the context of how genes and development have changed throughout time, as well as how this process has been shaped by the history of the planet. It's clear that there are big, big gaps in the early record of vertebrate life. I'd love to see those filled, and we have gotten better tools for this imaging and making sense of it.

Jeanne C. Marsh

Jeanne C. Marsh is the George Herbert Jones Distinguished Service Professor in the Crown Family School of Social Work, Policy, and Practice and the Director of the Center for Health Administration Studies. Marshs work focuses on health services research that looks at the integration of health and social services.

Currently, Marsh is focusing on the health disparities area; her team is studying the impact of substance abuse treatment on client functioning, specifically in women and children. One of the studies that she is leading is a study in Los Angeles County on the opioid epidemic. They are looking closely at not only gender disparities, but also race and ethnic disparities and how they can help improve access to treatment for these marginalized populations.

I think one hallmark of my work is a sense that we really need to do whatever data collection is necessary to hear directly from the people who are in the real world experiencing these issues, Marsh said. It isn't good enough just to pick up a big data set and run some analysis, it's really important to get the perspective of the people who are engaged in the process, who may be receiving the services.

One of the most significant parts of Marshs research has been becoming increasingly aware of health disparities which stem from broader social inequities. Findings from my research show that targeting health and social services to specific client needs significantly improves their health and social functioning, Marsh said. I bring a social work perspective to this research indicating that asking clients what health and social services they need and then providing them improves client outcome and satisfaction when compared to alternative approaches.

Marsh is also taking part in a new project that involves faculty members from both the Department of Medicine and the Crown Family School. They are primarily interested in health care for the disadvantaged, specifically in Medicare and Medicaid data. That's really the exciting part about science, when you can work together with really smart people in the process of discovery, addressing whatever your curiosity might be.

Maria-Luisa Alegre

Professor of Medicine Maria-Luisa Alegres research focuses on the molecular mechanisms involved in organ transplants. One area is centered around tolerance, while the other is centered on studying the impact of different environmental factors, specifically microbiota.

Currently, Alegre and her team are working with mice to explore how the immune response is altered by the gut microbiota. Their goal is to answer the question of how the microbiota that colonizes the transplanted organ itself influences the immune response to that organ and the commensals that colonize the organ. They are also working on figuring out what components of the immune system are being awakened to reject the organ when challenges that can threaten tolerance arise, such as severe infections.

Her goal for her research ultimately goes back to making an impact in the clinic. We would like to get to a point where we understand the mechanisms that underlie transplantation tolerance well enough that we could translate that into the clinic and be able to follow and monitor the cells of patients who are transplanted, Alegre said.

Edward Blucher

Edward Blucher is a Professor of Physics whose research focuses on particle physics. His studies center around exploring the imbalance that built up in the first millionth of a second or so during the Big Bang. Almost everything I have been studying is broadly connected by one big physics question, which is trying to better understand what happened early in the universe between matter and antimatter.

One of Bluchers most significant discoveries was on symmetry violation. We were looking for a very particular kind of violation in the way that a kaon decayed. In 1999, we finally found that this symmetry violation existed. It was very exciting because this was the kind of thing that would be needed for the universe to evolve the way it had existed in nature, Blucher said.

Blucher then developed an interest in neutrinos and their role in how the universe evolved to be imbalanced in matter and antimatter, and this is when DUNE was started. DUNE is an experiment that involved about 1400 physicists from 35 countries. It focused on looking for a violation of this matter and antimatter asymmetry in neutrinos by sending a beam of particles of neutrinos from Fermilab all the way to South Dakota.

Blucher is now working on an experiment that is also deep underground in a mine in northern Ontario that is looking at a rare type of nuclear decay. I think that asking about asymmetry is just a fascinating question, because it's something that we wouldn't be here without, Blucher said. It's a question that's really connected with how matter exists at all.

Go here to read the rest:
2021 AAAS Fellows Share Their Experience in Scientific Research - The Chicago Maroon

Posted in South Dakota Stem Cells | Comments Off

Cancer and Nanotechnology – National Cancer Institute

Posted: April 19, 2022 at 2:20 am

The NCI Cancer Nanotechnology Plan is a strategic document used by the NCI to guide the nanotechnology and onocoolgy fields in the future. The 2015 version is downloadable from this page.

Credit: National Cancer Institute

Currently, scientists are limited in their ability to turn promising molecular discoveries into cancer patient benefits. Nanotechnology the science and engineering of controlling matter, at the molecular scale, to create devices with novel chemical, physical and/or biological properties can provide technical control and tools to enable the development of new diagnostics, therapeutics, and preventions that keep pace with todays explosion in knowledge.

Nanotechnology has the potential to radically change how we diagnose and treat cancer. Although scientists and engineers have only recently (ca. 1980's) developed the ability to industrialize technologies at this scale, there has been good progress in translating nano-based cancer therapies and diagnostics into the clinic and many more are in development.

Nanotechnology is the application of materials, functionalized structures, devices, or systems at the atomic, molecular, or macromolecular scales. At these length scales, approximately the 1-100 nanometer range as defined by the U.S. National Nanotechnology Initiative (NNI) , unique and specific physical properties of matter exist, which can be readily manipulated for a desired application or effect. Furthermore, nanoscale structure can be used as individual entities or integrated into larger material components, systems, and architectures.

Nanoscale devices are one hundred to ten thousand times smaller than human cells. The depiction displays this scale in size.

Credit: National Cancer Institute

This emerging field involves scientists from many different disciplines, including physicists, chemists, engineers, information technologists, and material scientists, as well as biologists. Nanotechnology is being applied to almost every field imaginable, including electronics, magnetics, optics, information technology, materials development and biomedicine. Nanotechnology-based structures and devices are already enabling a large number of novel applications in various fields including medicine.

Nanotechnology offers many possible benefits to cancer therapy, detection and diagnosis. The benefits begin by way of the fundamental properties of nanotechnology and the biological challenges of which it can help to overcome.

In cancer, half the battle is won by its earlier detection and enhanced diagnosis. Furthmore, tools to enable precise monitoring of patient response to therapy can optimize therapy and improve patient outcomes. Find out how nanotechnology is and will continue to offer powerful solutions to these areas.

Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.

As far back as 1995, nanotechnology has offered clinicians novel tools to treat patients. Find a list of the currently approved nano-enabled therapeutics here.

Nanotechnology continues to progress into the clinic with more advanced tools than before and for more clinical indications or tumor types. Find a list of current clinical trials actively recruiting patients for these novel solutions.

Visit link:
Cancer and Nanotechnology - National Cancer Institute

Posted in Nano medicine | Comments Off

Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 – Digital Journal

Posted: April 19, 2022 at 2:20 am

The latest and updated research report on the GlobalNanobots/NanorobotsMarket covers a comprehensive overview of theNanobots/Nanorobotsmarket, future economic condition, competitive landscape mapping, supply and demand trends, and production and consumption analysis. The report also covers the influence of the COVID-19 pandemic on theNanobots/Nanorobotsmarket. The pandemic has dynamically affected all aspects of life on a global scale along with drastic changes in the economy and market conditions. The report covers the currently fluctuating market scenario along with present and future assessment of the COVID-19 impact. The report encompasses the historical data, company overview, financial standing, and necessary information about the new and key players of the market.

Magnetically guidedNanobots/Nanorobotssegment revenue is expected to register a significantly rapid rate during the forecast period. This can be attributed to increasing demand for delicate applications as magnetically guided nanorobots provide high degree of maneuverability in complex procedures.Nanobots/Nanorobotsis employed to carry and deliver live cells to targeted areas in the body, which further expected to advance, and this is expected to continue to drive revenue growth of this segment over the forecast period.

Rising investment in urgent care and increasing global geriatric population are key factors driving revenue growt of the global Nanobots/Nanorobots market

Nanobots/Nanorobots Market Size USD 6.12 Billion in 2020, Market Growth at a CAGR of 10.9%, Market Trends Advancements in technology

Get a Free sample of the report :https://www.emergenresearch.com/request-sample/744

Nanobots/Nanorobots are being used to perform complex tasks and procedures and help to reduce human error in various procedures and test in the healthcare industry. Latest studies in DNA nanotechnology support large-scale utility of nanorobots in the healthcare industry. Long-term returns derived from nanobots is encouraging market players to enter into long-term partnerships and to invest majorly in further research and development in nanotechnology. Upsurge in demand for miniaturized devices along with rapid rate of automation across various sectors are other factors fueling market revenue growth. Advancements in features ofNanobots/Nanorobotswill further drive market growth. However, increase in complexities with miniaturization is a key factor hampering revenue growth of the market currently.

Major players in the market include Bruker, Oxford Instruments, Toronto Nano Instrumentation, JEOL Ltd., Imina Technologies, Klocke Nanotechnik, Thermo-Fisher Scientific Inc., Ginkgo Bioworks, Agilent Technologies, and Park Systems.

The report offers a comprehensive overview of the competitive landscape and covers company profiles, production and manufacturing capacity, product portfolio, expansion strategies, and business initiatives such as mergers and acquisitions, joint ventures, collaborations, partnerships, and product launches and brand promotions among others.

Nanomedicine segment accounted for largest revenue share in 2020 due to its commercialization in the healthcare industry on large scale for drug delivery, in vitro diagnostics, in vivo imaging, biomaterial, drug therapy, and active implants.

In March 2021, Bionaut Labs, which is a company that is developing nanorobots to deliver drugs for treatment of brain diseases, announced that it had received a funding of USD 20 million led by Khosla Ventures and Upfront Ventures. The funds will be used to guide Bionaut Labs through clinical and preclinical development of its nanorobot technology.

North America accounted for largest revenue share in 2020 due to high spending on healthcare and increased investment in research development of nanotechnology. Another contributing factor is increased demand forNanobots/Nanorobotsfrom the National Science Foundation (NSF) and the Defense Advanced Research Projects Agency (DARPA). Various clinical trials and pipeline projects in the U.S. for development ofNanobots/Nanorobotsin various areas are also fueling market revenue growth.

Nanobots/Nanorobotsis the technology which creates robots or machines at a very small scale. The field ofNanobots/Nanorobotsbrings together various disciplines, including nanofabrication processes used for producing nanoactuators, nanomotors, and nanosensors, among others. Rising focus on regenerative medicine coupled with technological advancements is boosting market revenue growth. Furthermore, increasing adoption of medical equipment and more advanced technologies such as Machine Learning (ML) and Artificial Intelligence (AI) is driving growth of the globalNanobots/Nanorobotsmarket, and the trend is expected to continue going ahead.

For the purpose of this report, Emergen Research has segmented the globalNanobots/Nanorobotsmarket based on type, application, and region:

Nanomanipulator

Electron Microscope (EM)

Scanning Electron Microscope (SEM)

Transmission Electron Microscope (TEM)

Scanning Probe Microscope (SPM)

Atomic Force Microscopes (AFM)

Scanning Tunneling Microscope (STM)

Type Outlook (Revenue, USD Billion; 20182028)

Bio-Nanobots/Nanorobots

Magnetically Guided

Bacteria-Based

Application Outlook (Revenue, USD Billion; 20182028)

Nanomedicine

Biomedical

Mechanical

Others (Space and Oil Gas)

Elucidating the competitive landscape of theGlobalNanobots/NanorobotsMarket:

The globalNanobots/Nanorobotsmarket report offers viable insights into the competitive spectrum of theNanobots/Nanorobotsbusiness sphere.

The report systematically profiles the company information of each market player.

It identifies the estimated industry share, production facilities, development prospects, and geographies served by each market player.

The study showcases the extensive product portfolios of the prominent market contenders.

It offers critical data information about the product application scope and the end-user landscape.

The study provides salient information about the pricing models of the products offered by these companies. Moreover, it determines the gross profits and losses experienced by them throughout their market tenures.

Market Taxonomy:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2:

Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3:

Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4:

Regional Landscape

Chapter 5:

Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

Key geographical areas:

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Request customization of the report:https://www.emergenresearch.com/request-for-customization/744

Related reports:

Patient Engagement Solutions Market:https://www.emergenresearch.com/industry-report/patient-engagement-solutions-market

Nucleic Acid Isolation and Purification Market:https://www.emergenresearch.com/industry-report/nucleic-acid-isolation-and-purification-market

Non-Invasive Prenatal Testing Market: https://www.emergenresearch.com/industry-report/non-invasive-prenatal-testing-market

In-Vitro Fertilization Market: https://www.emergenresearch.com/industry-report/in-vitro-fertilization-market

Blockchain in Healthcare:https://www.forbes.com/sites/forbestechcouncil/2021/12/07/four-key-medtech-software-development-trends-for-2022/?sh=23e843f420d5

About Us:At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail:[emailprotected]

Facebook|LinkdIn|Twitter|Blogs

The post Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 appeared first on Market O Graphics.

Read the original:
Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal

Posted in Nano medicine | Comments Off

ERDC researchers analyze resilience in nanotechnology supply chains – erdc.usace.army.mil

Posted: April 19, 2022 at 2:20 am

VICKSBURG, Miss. Researchers at the U.S. Army Engineer Research and Development Center (ERDC) are analyzing the need for increased resilience in nanotechnology supply chains.

Manufacturing and distribution of products requires a complex network of suppliers and distributors that constitute supply chains. In todays world, most people are aware of supply chains and have probably been affected by supply chain disruptions caused by the COVID-19 pandemic.

Supply chains are pivotal in the production of both military and civilian products and technologies, said Dr. Igor Linkov, senior scientific technical manager for ERDCs Environmental Laboratory (EL). Our team looked at two questions: a) how do you assess the impacts of supply chain disruptions on the manufacturing bottom line and product availability to consumers, and b) how do you mitigate supply chain disruption and increase their ability to recover, particularly when the various secondary or tertiary contributors to a supply chain are poorly characterized?

In the past, supply chains were optimized to be efficient and lean. Companies like suppliers with low labor costs and predictable and inexpensive material availabilities; suppliers having mature capabilities to ship basic or composite materials to manufacturing centers and consumers alike are also popular. However, when there is a crisis and supply chains are disrupted, efficiency may not equal the ability to recover from the disruption.

For example, it is efficient to have one supplier that covers all the material requirements for a given product, but it is not resilient because if that supplier is disrupted then the whole supply chain is impacted. On the other hand, having multiple suppliers for each component may not be efficient because of the extra costs required to maintain multiple suppliers with variable product lines, but if one supplier is disrupted, other suppliers are available, and the supply chain is less disrupted and far more capable of expeditious recovery.

The biggest thing is to understand how to balance efficiency and resilience in supply chains, Linkov said. Understanding this, organizations can work to create a more resilient supply chain for the products and services they provide.

In addition to analyzing supply chains in general, the ERDC research team also looked at supply chains as they relate to the nanotechnology industry and specifically to COVID vaccine production. Their results are published in recent paper in the journal Vaccine (https://www.sciencedirect.com/science/article/pii/S0264410X22001724?via%3Dihub), as well as in Current Opinion in Chemical Engineering (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549437/).

This research, as well as other ERDC work related to climate response and recovery, is led by Dr. Benjamin Trump, a research social scientist in ELs executive office.

Nanotechnology is an emerging technology that is the manipulation of matter on an almost atomic scale to produce new structures, materials and devices. Nanotechnology is helping to improve many technology and industry sectors, including medicine, transportation and environmental science.

One thing we looked at was the nanotechnology supply chain as it applied to vaccines, said Trump. Nano-enabled components are quickly becoming vital to vaccine production. COVID-19 vaccine candidates, for instance, used nano-enabled components to improve vaccine efficacy and delivery in vivo.

Nanotechnology allows properties of materials to be changed in a controlled way to address specific needs. In military applications, nanomaterials are used to make warfighters clothing waterproof and self-cleaning. Nanomaterials can also be used to heal wounds nanomaterials can make a shirt automatically act as an antiseptic if the warfighter is wounded.

We have tried to attract attention to the problem that in manufacturing nano-enabled products, supply chain operations are foundational logistical challenges that require careful governance, Trump said. We tried to look at how supply chain works for nano-enabled products and use this as a way to illustrate the importance of resilience and efficiency in supply chains.

Here is the original post:
ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil

Posted in Nano medicine | Comments Off

Monthly Archives: April 2022

Pacritinib Added to NCCN Recommendation for Treatment in MPNs – Targeted Oncology

Behavioral health experts discuss the need for medical and behavioral reintegration and how to fill access gaps in Utah – State of Reform

Your Healthy Family: Rise in cancer is unintended consequence of pandemic – FOX 4 News Fort Myers WFTX

8 Early Signs You Have Lung Cancer, According to Doctors Eat This Not That – Eat This, Not That

Allergies May Come With Heightened Risk of Heart Problems | The Weather Channel – Articles from The Weather Channel | weather.com – The Weather…

Harper Care preps up with $6.5 million dosage to boost AI-based mental healthcare – Tech.eu

2021 AAAS Fellows Share Their Experience in Scientific Research – The Chicago Maroon

Cancer and Nanotechnology – National Cancer Institute

Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 – Digital Journal

ERDC researchers analyze resilience in nanotechnology supply chains – erdc.usace.army.mil

Categories

Archives

Recommended Sites

Contact Us

Recent Posts